• In this study we have generated new FRET

  2023-08-11

  

  In this study, we have generated new FRET reporters to screen all submembrane domains of AT1R for interactions with CaM. We identified a new CaM-binding domain on the receptor’s SMD2 (a.a. 125 – 141), confirmed interactions at SMD4JM (a.a. 309 – 327) and characterized the full interacting domain in

• br Stress glucocorticoids as risk factor

  2023-08-11

  

  Stress/glucocorticoids as risk factor for Alzheimer’s Disease: preclinical studies A role for glucocorticoids in shaping the risk for AD is supported by animal studies using rats or mice injected with Aβ oligomers, tau protein or excitotoxins, or transgenic (Tg) mice carrying mutations associated

• Sixth significant progress has been made during the last few

  2023-08-11

  

  Sixth, significant progress has been made during the last few years regarding the molecular mechanisms underlying the activation of AMPK and this should aid to develop more potent and specific compounds. Information from crystallographic structures combined with computer-based drug design hold promi

• Some of the mechanisms that

  2023-08-11

  

  Some of the mechanisms that involve 12-LOX as a potential pathogenic enzyme are illustrated in Fig. 2. Direct β cell effects associated with the stimulation of 12-LOX activity include the activation of second messengers c-Jun N-terminal kinase and p38 MAPK, both of which show increased phosphorylati

• Liao and van Linden et al

  2023-08-11

  

  Liao [47] and van Linden et al. [48] divided the gap between the N-terminal and C-terminal lobes into a front cleft or pocket, a gate area, and a back cleft. The back pocket corresponds to the gate area and the back cleft. The front cleft includes the Gly-rich loop, the hinge, the linker connecting

• br Results and discussion br Conclusion

  2023-08-11

  

  Results and discussion Conclusion The tyrosine kinase ALK represents one of the most successful molecular targets for the development of precise medicine to treat stratified subgroups of cancer patients. Three generations of ALK inhibitors have been awarded the FDA's approval or are being exte

• br Development of lorlatinib from crizotinib

  2023-08-11

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Calcium Ionophore I Additionally we were prompted to validat

  2023-08-11

  

  Additionally, we were prompted to validate the protective effect of ALDH3A1 by utilizing a human corneal model. Cornea is located in the anterior segment of the eye and thus, is constantly exposed to various environmental stressors that affect the cellular oxidative balance and consequently lead to

• When added to the culture medium extracellular ATP is metabo

  2023-08-11

  

  When added to the culture medium, extracellular ATP is metabolized into adenosine by ectonucleotidases, and ARs are then activated by adenosine with concentrations in the micromolar range [27]. However, our study showed that activation of ARs by exogenous adenosine could not induce the odontoblastic

• GSK1838705A Based on our previous work and the observation t

  2023-08-11

  

  Based on our previous work [13] and the observation that SNX9 is a partner for ACK, we have investigated interactions involving the SH3 domain of SNX9, and identified for the first time synaptojanin-1 as an alternate partner. This SH3 domain can bind a single site in ACK1, but multiple sites in the

• Introduction The lysosomal storage disorder Gaucher disease

  2023-08-11

  

  Introduction The lysosomal storage disorder Gaucher disease (Mendelian Inheritance in Man, OMIM #230800) results from the recessively inherited deficiency of lysosomal glucocerebrosidase (GCase, EC 3.2.1.45), caused by mutations in the gene GBA1 (MIM# 606463) located on chromosome 1q21. The enzymat

• br COX and LOX in post mortem AD

  2023-08-11

  

  COX and 5-LOX in post-mortem AD brain Minghetti (2004) reviewed the findings on COX-2 mRNA levels in AD brains, pointing out that the available evidence demonstrated either decreased or increased levels, possibly because of the short half-life of COX-2 transcripts or individual variability. Histo

• bez235 The central problem in amnesia

  2023-08-11

  

  The central problem in amnesia developing following impairment of long-term memory consolidation or reconsolidation is a question of the underlying mechanisms, whether it is caused by impairment of retrieval or memory storage mechanisms [3,8,9,[15], [16], [17], [18]]. To answer this question, severa

• br Materials and methods br Results br Discussion br Author

  2023-08-11

  

  Materials and methods Results Discussion Author contributions JH purified protein, performed vanadate inhibition experiments, crystallized, collected data, determined and refined the ATX-VO5 structure, analysed all the structures, prepared the displayed items and supervised ALHE; WJK con

• br Results and discussion br Conclusion A

  2023-08-11

  

  Results and discussion Conclusion A series of aminobenzothiazole derivatives were investigated as possible Aurora B kinase inhibitors. Bioisosteric replacement of the heterocyclic core of the lead compound was performed regarding the docking analysis. Replacement of the oxygen HS-173 of the b

16171 records 313/1079 page Previous Next First page 上5页 311312313314315 下5页 Last page